Kent Shih, MD
Hematology & Oncology · Nashville, TNNPI 1619075207
Payments from drug & device makers
Across 1,227 payments — averaging $1397.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$473K
- Novartis$427K
- Regeneron Healthcare Solutions, Inc.$297K
- Regeneron$180K
- Beigene, Ltd.$96K
- Genmab U.S., Inc.$65K
- plus $176K from 54 others
Across 1 payment — averaging $261.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$261
What the payments were for
- Consulting fees$118,74013%
- Speaking & faculty fees$692,07477%
- Travel & lodging$66,6627%
- Food & beverage$21,9572%
- Education$2660%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,714,691 in reported general payments places this provider in the 85th percentile of 251 hematology & oncology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 72 | $1,149,398 |
| LenvimaLenvatinib Mesylate | 12 | $264,156 |
| TagrissoOsimertinib Mesylate | 16 | $254,632 |
| TasignaNilotinib Hcl | 12 | $226,721 |
| CabometyxCabozantinib S-Malate | 13 | $205,067 |
| JakafiRuxolitinib Phosphate | 14 | $182,845 |
| KisqaliRibociclib Succinate | 13 | $175,560 |
| PromactaEltrombopag Olamine | 12 | $153,912 |
| BrukinsaZanubrutinib | 16 | $140,624 |
| EliquisApixaban | 69 | $49,477 |
| OrgovyxRelugolix | 11 | $32,633 |
| Abiraterone Acetate | 13 | $29,250 |
| GleostineLomustine | 14 | $17,435 |
| XareltoRivaroxaban | 11 | $6,027 |
| Sirolimus | 15 | $4,056 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $3,433 | $1,149,39872 claims |
| NovartisTasigna, Kisqali, Promacta | $427,093 | $556,19337 claims |
| Eisai Inc.Lenvima | $259 | $264,15612 claims |
| AstraZenecaTagrisso | $6,657 | $254,63216 claims |
| Exelixis Inc.Cabometyx | $119 | $205,06713 claims |
| Incyte CorporationJakafi | $192 | $182,84514 claims |
| PfizerEliquis | $271 | $49,47769 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $50 | $32,63311 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $150 | $29,25013 claims |
| Johnson & JohnsonXarelto | $33,525 | $6,02711 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $73 | $38342 claims |
| Lilly USA, LLCOlanzapine | $114 | $26440 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 251 hematology & oncology providers in Tennessee.
Other hematology & oncology in Nashville
- Erika HamiltonNashville$45.4M
- Ian FlinnNashville$41.2M
- Johanna BendellNashville$28.5M
- Jesus BerdejaNashville$22.2M
- Meredith McKeanNashville$16M
- Krish PatelNashville$14.2M
- Denise YardleyNashville$13.2M
- Todd BauerNashville$10.9M
- Wade IamsNashville$8.9M
- Benjamin GarmezyNashville$8.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.